Department of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China.
Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Medical University, Taiyuan, China.
Front Immunol. 2022 Sep 30;13:1022677. doi: 10.3389/fimmu.2022.1022677. eCollection 2022.
Previous studies find that long noncoding RNA human leukocyte antigen complex P5 (HCP5) is regarded as an oncogene accelerating cancer cell growth, invasion, metastasis, vascularization, and drug resistance in renal cell carcinoma, gastric cancer, and colorectal cancer. Nevertheless, the effect and regulatory mechanism of HCP5 in laryngeal squamous cell carcinoma (LSCC) remains unknown. In this study, HCP5 expression levels were confirmed to be prominently raised in LSCC cell lines. HCP5 knockdown reduced cell proliferation and migration and invasive ability of LSCC cell lines. Furthermore, miR-216a-5p was confirmed to sponge HCP5, and its expression was prominently downregulated in LSCC cell lines and upregulated in HCP5-silenced LSCC cell lines. miR-216a-5p overexpression downregulated the cell proliferation and migration and invasive ability of LSCC cells. Additionally, the protein level of zinc finger E-box binding homeobox 1 (ZEB1), one target gene of miR-216a-5p, was highly expressed in LSCC cell lines, and its expression level was downregulated by HCP5 knockdown and miR-216a-5p overexpression. An miR-216a-5p inhibitor reversed the effect of HCP5 knockdown on the proliferation and migration and invasive ability of LSCC cells. In conclusion, knocking down HCP5 may be a strategy to suppress the malignant biological function regulating miR-216a-5p/ZEB1. Therefore, HCP5 may become a prospective therapeutic target for LSCC.
先前的研究发现,长链非编码 RNA 人类白细胞抗原复合物 P5(HCP5)被认为是一种癌基因,可加速肾癌、胃癌和结直肠癌中的癌细胞生长、侵袭、转移、血管生成和耐药性。然而,HCP5 在喉鳞状细胞癌(LSCC)中的作用和调节机制尚不清楚。在本研究中,证实 HCP5 的表达水平在 LSCC 细胞系中明显升高。HCP5 敲低降低了 LSCC 细胞系的细胞增殖、迁移和侵袭能力。此外,证实 miR-216a-5p 可与 HCP5 结合,其在 LSCC 细胞系中的表达明显下调,而在 HCP5 沉默的 LSCC 细胞系中上调。miR-216a-5p 的过表达降低了 LSCC 细胞的增殖、迁移和侵袭能力。此外,锌指 E 盒结合同源盒 1(ZEB1)是 miR-216a-5p 的一个靶基因,其在 LSCC 细胞系中的蛋白水平表达较高,且其表达水平可被 HCP5 敲低和 miR-216a-5p 过表达下调。miR-216a-5p 抑制剂逆转了 HCP5 敲低对 LSCC 细胞增殖、迁移和侵袭能力的影响。总之,敲低 HCP5 可能是一种抑制调节 miR-216a-5p/ZEB1 的恶性生物学功能的策略。因此,HCP5 可能成为 LSCC 的一个有前途的治疗靶点。